13 May FSHD NEWS: Resolaris Improves Muscle Strength, Quality of Life in FSHD Patients, Study Finds
This story was originally published on musculardystrophynews.com on April 27, 2017. Resolaris, a protein therapy developed for rare muscle diseases by aTyr Pharma, improved muscle strength and quality of life in a small study of patients with early onset facioscapulohumeral muscular dystrophy (FSHD). These findings, as well as others...